Weekly Psychedelic Policy Briefing β August 16, 2026
Resilient Pharmaceuticals has resubmitted its New Drug Application for MDMA-assisted therapy for PTSD, without the new Phase 3 trial the FDA asked for. Canada funds a C$24 million cannabis and brain health consortium, and Definium's oral LSD tablet clears Phase 3 in generalized anxiety disorder. The post Weekly Psychedelic Policy Briefing β August 16, 2026 appeared first on Psychedelics Today.
External link. We are not responsible for the content.
Read more βMore From Psychedelics Today
Horizons: Perspectives on Psychedelics
Please join us this autumn for the 19th Horizons conference on October 15-17 in New York City. This is one of the imp...
Why Perimenopause Belongs in Psychedelic Research
Perimenopause is one of the least-researched transitions in women's health. Some women are already microdosing San Pe...
Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
What happens when a psychedelic experience continues causing problems long after the trip ends? Emory researchers Jos...
Latest News
Orchidaceaen Ethics 1
On acid, ancient philosophy, and the problem of knowing
Would You Recognize Abuse in Ceremony? If So, What Do You Do?
"The Psychedelic Seeker's Guide" dives into abusive practitioners and what you should do if you witness abuse in psyc...
Altered βstateβ vs Altered βsense of selfβ
Psychedelic culture has given us a powerful image of transformation: the self dissolves, the familiar world disappear...
Whatβs the difference between recreational and therapeutic psychedelic use? 5 Questions with experimental psychologist Harriet de Wit
De Wit discusses the difficulty of finding out what a drug does, outside of its context.
World Ayahuasca Forum Brings Ancestral Intelligence to Spain
PLUS, an interview with an iconic Grateful Dead artist, ayahuasca and loneliness, and Puerto Rico's executive order. ...
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating β all remain valid when formalising your anecdotal report, to make sense...